Biswa Misra
@biswamisra.bsky.social
BiOmician #Delhite #Omics #Drugs |Alumni: @IITKgp @ETH_en @USMOfficial1969 @UF @txbiomed @wakehealth| Director #Metabolomics Innov. @envedabio|
🧔♂️. “Do you know you can share RAW #untargeted #LCMS & #GCMS #metabolomics datasets at 3 different repositories:
1. #MetaboLights
2. #GNPS/ #Massive
3. #MetabolomicsWorkbench”
🧔♀️ “Whaaaat, for free and with ease?”
1. #MetaboLights
2. #GNPS/ #Massive
3. #MetabolomicsWorkbench”
🧔♀️ “Whaaaat, for free and with ease?”
June 17, 2025 at 5:52 PM
🧔♂️. “Do you know you can share RAW #untargeted #LCMS & #GCMS #metabolomics datasets at 3 different repositories:
1. #MetaboLights
2. #GNPS/ #Massive
3. #MetabolomicsWorkbench”
🧔♀️ “Whaaaat, for free and with ease?”
1. #MetaboLights
2. #GNPS/ #Massive
3. #MetabolomicsWorkbench”
🧔♀️ “Whaaaat, for free and with ease?”
More than a clinical milestone – this marks real momentum for our lead asset.
Our first-in-class oral therapeutic, ENV-294, cleared a major Phase I milestone with favorable safety results and it's showing potential to transform care for #atopicdermatitis patients.
#DrugDiscovery #AI #ClinicalTrials
Our first-in-class oral therapeutic, ENV-294, cleared a major Phase I milestone with favorable safety results and it's showing potential to transform care for #atopicdermatitis patients.
#DrugDiscovery #AI #ClinicalTrials
May 29, 2025 at 2:58 AM
More than a clinical milestone – this marks real momentum for our lead asset.
Our first-in-class oral therapeutic, ENV-294, cleared a major Phase I milestone with favorable safety results and it's showing potential to transform care for #atopicdermatitis patients.
#DrugDiscovery #AI #ClinicalTrials
Our first-in-class oral therapeutic, ENV-294, cleared a major Phase I milestone with favorable safety results and it's showing potential to transform care for #atopicdermatitis patients.
#DrugDiscovery #AI #ClinicalTrials
🚀 We’ve been backed by leading investors behind #SpaceX, #amazon, and other world-changing companies, adding one of the biggest names in #pharma to our list.
Today, we’re excited to share that #Sanofi has joined our Series C, bringing the total raise to $150M!
🔗 businesswire.com/news/home/2025…
Today, we’re excited to share that #Sanofi has joined our Series C, bringing the total raise to $150M!
🔗 businesswire.com/news/home/2025…
February 26, 2025 at 6:14 PM
🚀 We’ve been backed by leading investors behind #SpaceX, #amazon, and other world-changing companies, adding one of the biggest names in #pharma to our list.
Today, we’re excited to share that #Sanofi has joined our Series C, bringing the total raise to $150M!
🔗 businesswire.com/news/home/2025…
Today, we’re excited to share that #Sanofi has joined our Series C, bringing the total raise to $150M!
🔗 businesswire.com/news/home/2025…